EU/3/14/1356: Orphan designation for the treatment of acute myeloid leukaemia

Donor T lymphocytes depleted ex-vivo of host alloreactive T cells using photodynamic treatment

Overview

On 19 November 2014, orphan designation (EU/3/14/1356) was granted by the European Commission to Kiadis Pharma Netherlands B.V., the Netherlands, for donor T lymphocytes depleted ex-vivo of host alloreactive T cells using photodynamic treatment for the treatment of acute myeloid leukaemia.

Please note that this product was withdrawn from the Union Register of orphan medicinal products in February 2022 on request of the Sponsor.

Key facts

Active substance
Donor T lymphocytes depleted ex-vivo of host alloreactive T cells using photodynamic treatment
Intended use
Treatment of acute myeloid leukaemia
Orphan designation status
Withdrawn
EU designation number
EU/3/14/1356
Date of designation
19/11/2014
Sponsor
Kiadis Pharma Netherlands B.V
Entrada 231-234
1114 AA Amsterdam-Duivendrecht
The Netherlands
Tel. +31 20 314 0250
Fax +31 20 314 0251
E-mail: info@kiadis.com

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Related content

How useful was this page?

Add your rating